EverGlade Insights Archives - EverGlade Consulting

EverGlade Insights

ASPR RFI on Essential Medicines Industrial Base

ASPR Industrial Base Management and Supply Chain Request for Information (RFI) Strengthening the U.S. Pharmaceutical Supply Chain: ASPR’s Essential Medicines RFI The U.S. Department of Health and Human Services (HHS), through its Administration for Strategic Preparedness and Response (ASPR), recently issued a Request for Information (RFI) to industry partners regarding domestic manufacturing capabilities for essential […]

ASPR RFI on Essential Medicines Industrial Base Read More »

NIH Guidance on International Subcontracting

Maximizing the Value of Foreign Collaborations While Safeguarding U.S. Investments The National Institutes of Health (NIH), the nation’s primary medical research agency, recently issued guidance on the use of international subcontractors in NIH-funded research. This announcement reflects NIH’s dual mission: advancing health outcomes for Americans while ensuring responsible stewardship of U.S. taxpayer dollars. While global

NIH Guidance on International Subcontracting Read More »

The NIH’s Strategic Plan for Autoimmune Disease Research

Enhancing Innovation, Collaboration, and Impact Autoimmune diseases are one of the most significant and complex public health challenges of our time. Affecting an estimated 23.5 to 50 million Americans, these conditions range from rheumatoid arthritis and type 1 diabetes to multiple sclerosis and lupus, impacting nearly every organ system and disproportionately affecting women (over 80%

The NIH’s Strategic Plan for Autoimmune Disease Research Read More »

NIH’s New Policy on AI and Proposal Limits: What You Need to Know

NIH just released NOT-OD-25-132: “Supporting Fairness and Originality in NIH Research Applications.” There are two major changes that will shape how you plan and submit proposals beginning September 25, 2025: Originality & AI: NIH reiterates that applications must be the investigators’ original work and flags risks from AI-generated text (e.g., plagiarism, fabricated citations). Institutions should

NIH’s New Policy on AI and Proposal Limits: What You Need to Know Read More »

DOE unveils $1B in critical mineral funding

Introduction The U.S. Department of Energy (DOE) has announced nearly $1 billion in funding to strengthen domestic critical minerals supply chains. This initiative targets mining, processing, and manufacturing technologies for essential materials such as rare earths, battery components, and specialty elements. It represents a major opportunity for companies prepared to advance clean energy, semiconductors, and

DOE unveils $1B in critical mineral funding Read More »

Inside the New Executive Order on Strategic API Reserves

Introduction On August 13, 2025, President Trump signed a sweeping Executive Order titled “Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve.” The order addresses a long-standing vulnerability in the U.S. healthcare system, the nation’s heavy reliance on foreign suppliers for the active pharmaceutical ingredients (APIs) that make up the

Inside the New Executive Order on Strategic API Reserves Read More »

DTRA’s “Plume” RFI for Marine Toxin Aerosol Exposure Models

Advancing Countermeasures for Marine Toxin Threats The Defense Threat Reduction Agency (DTRA), through its Research and Development Chemical and Biological Technologies Directorate in support of the Joint Science and Technology Office (JSTO), has issued a Request for Information (RFI) titled “Plume”. This initiative seeks information on the capabilities and availability of suitable animal models for

DTRA’s “Plume” RFI for Marine Toxin Aerosol Exposure Models Read More »

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates

As the global health landscape evolves, so too must the United States’ ability to respond rapidly to biological threats. To strengthen its readiness posture, the Biomedical Advanced Research and Development Authority (BARDA), in coordination with the Administration for Strategic Preparedness and Response (ASPR), has released a new opportunity under the BioMaP Consortium OT Vehicle. This

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates Read More »

DARPA NODES

DARPA Launches NODES to Revolutionize Protein Function Prediction

DARPA-PS-25-30 Program Solicitation Network of Optimal Dynamic Energy Signatures (NODES) On July 31, 2025, the Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), released a new program solicitation titled Network of Optimal Dynamic Energy Signatures (NODES). This initiative seeks to unlock a deeper understanding of protein functions by moving beyond static

DARPA Launches NODES to Revolutionize Protein Function Prediction Read More »

DTRA RAVEN Program

DTRA’s Reimagining the Next Generation of Biodefense Vaccines

Reimagining the Next Generation of Biodefense Vaccines: DTRA’s RAVEN Opportunity The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO) and the Research and Development-Chem/Bio Medical Vaccines (RD-CBMV) division, has launched the Reimagining Available Vaccines and Envisioning Novelty (RAVEN) initiative. This forward-looking program is designed to modernize the nation’s medical countermeasure

DTRA’s Reimagining the Next Generation of Biodefense Vaccines Read More »

JPEO RFI u.s. military protective systems

U.S. Army Seeks Breakthrough Concepts to Combat Contaminant Infiltration in Protective Systems

Overview In a Request for Information (RFI), the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Protection (JPM CBRN P), has called on industry, academia, and non-traditional innovators to help reimagine how protective gear prevents the infiltration of harmful airborne particles and vapors. This initiative aims to address a longstanding issue known as the

U.S. Army Seeks Breakthrough Concepts to Combat Contaminant Infiltration in Protective Systems Read More »

organophosphorus nerve agents

Project UPREG

Project UPREG: DTRA’s Push for Enhanced Protection Against Nerve Agents The Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department, in its role as the Joint Science and Technology Office (JSTO), has launched Project UPREG, a bold initiative to develop next-generation medical countermeasures against organophosphorus nerve agents (OPNAs). These highly toxic compounds pose a

Project UPREG Read More »

Scroll to Top